Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

748156

registered interest
date	04/07/2017
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Ivory: Sales
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, when he plans to start the consultation exercise on a ban on the trade of ivory.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	2674
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>Bringing an end to elephant poaching is a priority for this government We are currently considering next steps and will set these out in due course.</p><p> </p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 11/07/2017 15:08:26 answering member 4098 label Biography information for Dr Thérèse Coffey
tabling member	4025 label Biography information for Mrs Pauline Latham

714583

registered interest
date	28/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to raise the NHS Improvement tariff for photodynamic therapy to cover the full cost of that procedure; and if he will make a statement.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	69535
answer	answer is ministerial correction date of answer 05/04/2017 answer text <p>NHS Improvement and NHS England have no plans to change the national prices for 2017/18 and 2018/19 for photodynamic therapy. However, providers and commissioners can agree to vary national prices where this would be in the best interest of patients. These ‘local variations’ can be agreed in accordance with National Tariff rules on locally-determined prices.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 05/04/2017 12:37:47 answering member 1542 label Biography information for Philip Dunne
tabling member	4025 label Biography information for Mrs Pauline Latham

711546

registered interest
date	15/03/2017
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Foreign Companies: Ownership
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to ensure that foreign companies which own properties in the UK publish details of their ultimate beneficial ownership.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	68151
answer	answer is ministerial correction date of answer 21/03/2017 answer text <p>The Government remains committed introducing the register of beneficial ownership for foreign companies that own UK property, which was announced at the Anti-Corruption summit in 2016.</p><p> </p><p>This register is an important element of the forthcoming anti-corruption strategy. It will give assurance that the UK is a hostile environment for hiding the proceeds of corruption or laundering money.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Stourbridge answering member printed Margot James question first answered 21/03/2017 14:29:01 answering member 4115 label Biography information for Margot James
tabling member	4025 label Biography information for Mrs Pauline Latham

692584

registered interest
date	21/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 20 February 2017 to Question 63820, if he will take steps to increase the maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund from two to three years.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	64926
answer	answer is ministerial correction date of answer 01/03/2017 answer text <p>There is no maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund (CDF). The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, the National Institute for Health and Care Excellence and the company concerned. The timeframe will normally be up to two years, but will be considered on a case by case basis.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 01/03/2017 13:42:43 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

688010

registered interest
date	09/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to increase the length of time that data is collected on the evaluation of treatment funded by the Cancer Drugs Fund.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	63820
answer	answer is ministerial correction date of answer 20/02/2017 answer text <p>NHS England has advised that cancer drugs that are assessed by the National Institute for Health and Care Excellence (NICE) as having both key clinical uncertainties and plausible cost effectiveness can enter the Cancer Drugs Fund (CDF) for evaluation with a view to future NICE re-appraisal once there is sufficient data from continuing clinical trials and/or data collection in the CDF.</p><p> </p><p>The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, NICE and the company concerned.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/02/2017 12:02:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

671974

registered interest
date	09/01/2017
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Roads: Repairs and Maintenance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what steps he is taking to improve the condition of local roads.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	908133
answer	answer is ministerial correction date of answer 12/01/2017 answer text <p>The Department’s road condition statistics highlight that local classified roads are improving, with fewer requiring maintenance. The Government is providing local highway authorities with over £6 billion between 2015 and 2021 for highways maintenance. We will soon be announcing how we will allocate a further £185 million for 2017/18 financial year, in addition to over £1 billion already committed, to improve the condition of local roads.</p> answering member constituency Harrogate and Knaresborough answering member printed Andrew Jones question first answered 12/01/2017 15:12:42 answering member 3996 label Biography information for Andrew Jones
tabling member	4025 label Biography information for Mrs Pauline Latham

657941

registered interest
date	13/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments: Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to prevent NHS England from imposing restrictions on patients' access to NICE-approved treatments for melanoma and other conditions; and if he will make a statement.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	57299
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57212 question first answered 20/12/2016 10:28:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

657942

registered interest
date	13/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Derbyshire Healthcare NHS Foundation Trust: Disciplinary Proceedings
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people have been suspended from the Derbyshire Mental Health Trust in the last two years; and for how long those suspensions were active.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	57293
answer	answer is ministerial correction date of answer 19/12/2016 answer text <p>The information requested is not available centrally. It may be obtained from Derbyshire Healthcare NHS Foundation Trust. We have written to Richard Gregory, Chair of the Trust, informing him of the hon. Member’s enquiry. He will reply shortly and a copy of the letter will be placed in the Library.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 19/12/2016 15:17:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham

657098

registered interest
date	12/12/2016
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Ivory
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, pursuant to the oral contribution by the Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs of 8 December 2016, Official Report, columns 188-9WH, whether her Department's proposals to widen the UK ban on ivory sales will include sales of ivory products dating from before 1947.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	57276
answer	answer is ministerial correction date of answer 15/12/2016 answer text <p>We have been actively exploring options to implement the Government’s manifesto commitment to press for a total ban on ivory sales and early next year we will consult on our proposal to ban sales of ivory that is less than 70 years old as of March 2017. As part of this, we plan to seek evidence on options and impacts of taking further action.</p><p> </p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 15/12/2016 15:20:53 answering member 4098 label Biography information for Dr Thérèse Coffey
tabling member	4025 label Biography information for Mrs Pauline Latham

657124

registered interest
date	12/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Skin Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what restrictions have been placed on patients accessing treatments for advanced (stage 4) melanoma by (a) NHS England, (b) his Department and (c) NICE.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	57212
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57299 question first answered 20/12/2016 10:28:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4025 label Biography information for Mrs Pauline Latham